ArticleBMC endocrine disorders2026
Hyperprolactinemia, hyperandrogenemia, pituitary adenoma, and metabolic disorders in Wiedemann-Steiner syndrome: a case report.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWiedemann-Steiner syndrome (WSS) is an autosomal dominant disorder caused by variants in the lysine-specific methyltransferase 2 A (KMT2A) gene. It is characterized by developmental delay, intellectual disability, hypertrichosis, growth retardation, and distinctive facial appearance. Reports on adult patients with WSS remain limited. CASE PRESENTATION: We report the case of a 26-year-old woman with WSS who presented with oligomenorrhea for 11 years and irregular menstruation for 2 years. Since birth, she had hypertrichosis on her back and extremities, growth and development retardation, and brachydactyly. She had been receiving antipsychotic treatment with risperidone and trihexyphenidyl for the past two years. Laboratory evaluation revealed hyperprolactinemia (prolactin 1062.96 mIU/L; reference range 59.00–619.00 mIU/L), hyperandrogenemia, impaired glucose tolerance, insulin resistance, and hyperuricemia. Magnetic resonance imaging showed a pituitary microadenoma, which was confirmed as non-functioning following comprehensive pituitary hormone assessment. Whole-exome sequencing identified a de novo variant in the KMT2A gene: c.173dupC (p.Ala59Glyfs*88). Regarding management, risperidone and trihexyphenidyl were switched to aripiprazole on psychiatric advice. Half a month after the medication change, prolactin decreased to 124.32 mIU/L and remained at 129.73 mIU/L six months later.
conclusionsClinicians should be aware of the risk of antipsychotic-induced hyperprolactinemia in patients with WSS receiving such treatment. Moreover, endocrine-related issues warrant greater attention in the clinical management of these patients, particularly in adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.